Background Different adjuvant treatments are available for patients with gastric cancer, but conventional meta-analyses performing direct comparisons between two alternative treatments did not have enough power to compare all the adjuvant treatments. Thus, we did a network meta-analysis summarizing the direct and indirect comparisons to identify the optimum treatment. Methods We systematically searched for RCTs of adjuvant treatments for gastric cancer comparing two or more of the following treatments: surgery alone, radiotherapy with fluoropyrimidine, S-1-based regimens, and XELOX. The treatments offering available indirect evidence to investigate the comparative effectiveness of adjuvant treatments mentioned above were also included. Then we performed a Bayesian network meta-analysis to summarize the direct and indirect comparisons. We estimated hazard ratios with 95% credible intervals (CrI) for OS and DFS. 
Introduction
Gastric cancer is the fifth most common cancer worldwide and the third most common cause of death from cancer, accounting for 6.8% of the total cases and 8.8% of total deaths with about 723,000 deaths in 2012 [1] . Surgery is the only curative treatment in patients with localized gastric cancer [2] , the overall survival (OS) remains poor for locoregional as well as distant recurrence after curative resection [3] . Thus, various adjuvant treatments including chemotherapy and chemoradiotherapy have been investigated to improve the surgical outcomes and prevent recurrence of the disease during the past decades, which was confirmed by several meta-analyses [4] [5] [6] . Efficacy has also been established for several adjuvant treatments in randomized controlled trials (RCTs) [7] [8] [9] [10] [11] [12] . The National Comprehensive Cancer Network (NCCN) guideline for the treatment of gastric cancer advised capecitabine and oxaliplatin (XELOX) as adjuvant chemotherapy regimens based on the results of the CLASSIC trial [7, 13] and radiotherapy with fluoropyrimidine as adjuvant chemoradiotherapy based on the INT-0116 trial [11] . On the other hand, S-1-based regimes and XELOX are recommended in Japanese gastric cancer treatment guidelines for the results of the ACTS-GC, J-CLASSIC, and SOX-adjuvant trials [8, [14] [15] [16] . Adjuvant chemotherapy including XELOX and S-1 and adjuvant chemoradiotherapy are both recommended in European Society for Medical Oncology (ESMO) guidelines [2] .
However, most of those postoperative adjuvant treatments have never been compared with each other for the lack of head-to-head trials and the limitation of traditional meta-analysis methods which could only perform direct pairwise comparisons. Thus, the most effective adjuvant treatment for resected gastric cancer is still unknown. D2 gastrectomy has been the standard of care for advanced gastric cancer in East Asia [14, 17] and recommended in western guidelines [2, 13] and the optimum treatment for patients undergoing D2 lymph node dissection also remains controversial. On the other hand, how to select different adjuvant treatment for the stage III gastric cancer has been the focus of public attention and identifying the more effective postoperative treatments for stage III disease is urgently needed.
We used a Bayesian network meta-analysis to investigate the questions. In the Bayesian hierarchical model, comparisons of two or more treatments are available by using indirect comparisons when there are no head-tohead, comparative studies, we can overcome the shortage of direct comparison trials and combine direct and indirect comparisons to compare several inventions at the same time [18] [19] [20] [21] . The aim of our network meta-analysis was to investigate and summarize the direct and indirect comparisons to derive the comparative effect of all included adjuvant treatments for resected gastric cancer.
Method

Search strategy
Two investigators performed a systematic literature search in PubMed, EMBASE (Ovid), Cochrane Library (Ovid) (last updated on May 30, 2017) without language restriction, using combinations of the following terms: "stomach neoplasms", "gastric cancer", "stomach cancer", "esophagogastric junction", "gastroesophageal junction", "adjuvant", "Postoperative", "chemotherapy, adjuvant", "Randomized Controlled Trial", "Controlled Clinical Trial" in accordance with the Cochrane Handbook for Systematic Reviews of Interventions [22] .
The reference list was also checked for relevant studies, and all studies were carefully evaluated to identify duplicate data.
Study selection
The following criteria were used for the study selection: (1) participants (P): patients were eligible if they had histologically proven gastric or gastroesophageal junction adenocarcinoma with no evidence of distant metastasis. (2) Interventions (I) and comparisons (C): we only included the RCTs of adjuvant treatments for gastric cancer comparing 2 or more of the following treatments: surgery alone, radiotherapy with fluoropyrimidine, S-1-based regimes, XELOX. The RCTs of adjuvant treatments offering available indirect evidence other than treatments mentioned above were also enrolled in the meta-analysis. Patients enrolled in the studies had no previous chemotherapy or radiotherapy. (3) Outcomes: OS, (the time between randomization and all-cause death) or disease-free survival (DFS), time between randomization and the first event of all-cause death, relapse of stomach cancer, or occurrence of a second cancer); (4) study design (S): published randomized controlled trials; (5) provided enough information to estimate hazard ratio (HR) and 95% confidence intervals (CIs) of OS or DFS.
Conference abstracts, letters, case reports, reviews, studies without randomization for treatment allocation or studies without usable data were excluded. Studies concerning intraperitoneal chemotherapy or immunotherapy were also excluded.
For the subgroup analysis for D2 lymph node dissection, only studies with extractable data of patients with D2 lymph node dissection were included. Studies with extractable data of patients with stage III gastric cancer were included in the subgroup analysis of stage III gastric cancer, staging classification was according to the American Joint Committee on Cancer (AJCC) cancer staging manual (sixth edition) [23] .
Assessment of risk of bias and data collection
Qualitative assessment and data extraction were finished by two investigators independently. Disagreements were resolved in discussion with a third investigator. The two researchers used the same standardized collection form to independently extract information from each enrolled study. We also extracted the HR and 95% CI to assess OS and DFS. Data concerning study quality, population characteristics and year of publication as well as interventions and outcomes were extracted.
The quality and the risk of bias of randomized controlled trials was assessed by Cochrane Collaboration's tool [24] .
Statistical analysis
The meta-analysis was performed according to PRISMA checklist [25] . The primary outcome of our network metaanalysis was OS, and the secondary outcomes were DFS. HRs which take the number and timing of events into consideration with its 95% CI were used to assess time-to-event outcomes, we obtained the data directly from the studies or used Kaplan-Meier survival curves to estimate the HRs of survival, which is reported by Tierney et al [22, 26] . 95% credible intervals (Crl) of HR for the estimates the network meta-analyses. An HR below 1 indicated a better prognosis with the experimental intervention.
The network meta-analyses using the Bayesian methods [18] was performed in Stata 12 (Stata Corp, College Station, TX, USA), JAGS and R (version x64 3.3.3) with the gemtc package (version: 0.8-2) and rjags package (version: 4-6) with a fixed-effect model, as most of the head-to-head comparisons only included one trial providing direct evidence.
The inconsistency of our results was also confirmed by the node-splitting method and its Bayesian P value [27] , comparing the direct and the indirect estimates for each comparison. We estimated the potential ranking probability of treatments by calculating the surface under the cumulative ranking curve (SUCRA) for each intervention [28] . The SUCRA index ranges between 0 (or 0%) and 1 (or 100%), where the treatments with higher SUCRA values are considered to have better efficacy.
Result
Study selection and characteristics
We systematically searched PubMed, EMBASE, the Cochrane Library for RCTs. A total of 3712 articles were considered to be potentially relevant and 11 studies [7] [8] [9] [10] [11] [29] [30] [31] [32] [33] [34] meeting the inclusion criteria were included in this meta-analysis. Literature screening process is shown in Fig. 1 .
The characteristics of included studies are summarized in Table 1 . Seven treatments were compared, and the network plots of all the comparisons analyzed are shown in Fig. 2 ; each of nodes included different interventions with specific plan of treatments: fluorouracil with or without leucovorin (5-FU); radiotherapy with fluorouracil (5-FU/RT); capecitabine, oxaliplatin (XELOX); cisplatin, epirubicin/epidoxorubicin, leucovorin, and fluorouracil (PELF); S-1-based regimes; UFT-based regimes. The size of the nodes and the thickness of the edges are weighted according to the number of studies evaluating each treatment and direct comparison, respectively. In total, our analysis included 5620 patients: 1769 treated with surgery alone; 283, 5-FU; 499, 5-FU/RT; 520, XELOX; 220, PELF; 1234, S-1-based regimes; 1095, UFT-based regimes.
Network meta-analysis
Overall survival
All the 11 trials contributed to our network meta-analysis of OS, comparing the 7 treatments. HRs were explicitly reported in 9 trials and also could be estimated in 2 trials [31, 34] . In Fig. 3A , we summarize the comparisons analyzed by the Bayesian network meta-analysis. The SUCRA values of 92 and 81% for S-1-based regimens and XELOX suggested that these were the two treatments with the highest chance of improving OS in resected gastric cancer. 5-FU and surgery only had the least chance of improving OS (Table 2) .
Disease-free survival
Nine trials [7-11, 29, 30, 32, 34] contributed to our network meta-analysis of DFS, comparing the 7 treatments. HRs were explicitly reported in 7 trials and could be estimated in 2 trials [30, 34] . In Fig. 3A , we summarize the comparisons analyzed by the Bayesian network meta-analysis. The SUCRA values of 89 and 86% for XELOX and S-1-based regimens, respectively, suggesting that these were the two treatments with the highest chance of improving DFS in resected gastric cancer, whereas 5-FU and surgery alone was least likely to be the best treatment strategy (SUCRA: 21% and SUCRA: 8%, respectively) ( Table 2 ).
D2 lymph node dissection
Five trials [7, 8, 10, 11, 29] reporting available data were included for meta-analysis of adjuvant treatments for resected gastric cancer with D2 lymph node dissection, comparing 5 treatments. The INT-0116 trial included several subgroups, the subset with D2 group was used for the analysis of OS for patients with D2 lymph node dissection [11] .
We summarized the results of our subgroup analysis for OS and DFS in Fig. 3B . Compared with surgery alone, S-1-based regimens, UFT-based regimens, and XELOX improved both OS and DFS. 5-FU/RT, however, demonstrated not enough statistical evidence available to support survival benefits for the patients with D2 level of resection when compared with surgery alone in terms of OS [HR = 0.93 with 95% CrI: (0.41,2.1)].
There was no statistically significant difference between S-1-based regimens and XELOX. The SUCRA values for XELOX and S-1-based regimens suggested that these were the two treatments with the highest chance of improving OS and DFS in resected gastric cancer (Table 2) .
Stage III gastric cancer
Two trials [7, 8] reporting available data were included for subgroup analysis of adjuvant treatments for resected stage III gastric cancer, comparing surgery alone, S-1 and XELOX. Results of subgroup analysis of stage III disease are shown in Table 3 
Quality of evidence
The bias assessment for eligible RCTs included in the network meta-analysis is shown in Online Resource 1 according to the Cochrane risk-of-bias tool, showing no severe risk of bias.
The result of the comparison-adjusted funnel plots for both OS and DFS in Fig. 4 did not show the evidence of apparent asymmetry, suggesting the absence of publication bias [35] . Tests for funnel plot asymmetry of the two subgroups were not conducted for the reason that there were fewer than 10 studies in both subgroups [36] . We also used the node-splitting analysis of outcomes with P value to confirm the consistency in any closed loops of the two outcomes; the results are shown in Online Resource 2. A P value < 0.05 indicates a significant inconsistency. According to the results, no consistency in any closed loop was detected with relevant P value lager than 0.05 by nodesplitting method. The absence of inconsistency between the direct and indirect comparison in all networks which was confirmed by both the node-splitting method coupled with the results of the bias assessment and the comparison-adjusted funnel plots allowed assessment of the network meta-analysis.
Discussion
To give valuable suggestions for choice of treatments through comparing their efficacy, we conducted the network meta-analysis to compare adjuvant treatments for gastric cancer in terms of OS and DFS. Our network meta-analysis is the first study to estimate the HRs for OS and DFS of pairwise comparisons of potential adjuvant treatments for gastric cancer and to provide the relative treatments ranking which serves as supportive information to explore the optimum treatment.
In the network meta-analysis, we combined direct and indirect evidence from 11 RCTs (11 for OS, 9 for DFS; 5 for subgroup analysis of the D2 lymph node dissection; 2 for subgroup analysis of stage III gastric cancer) and reported 3851 participants with resected gastric cancer followed by adjuvant treatments.
In the analysis of OS, our results suggested that adjuvant treatments with 5-FU/RT, S-1-based regimens, and XELOX provided an advantage over surgery alone, and the rest of the adjuvant therapies were not associated with an improved OS when compared with surgery alone. In accordance with the findings of the previous study [29] , our study demonstrated that UFT-based regimes were inferior to S-1-based regimes. No treatment was clearly superior to others between 5-FU/RT, S-1-based regimens; however, adjuvant S-1-based regimes and adjuvant XELOX showed a statistically non-significant trend to better survival as compared with 5-FU/RT. Taking the results of SUCRA into consideration, we suggested that S-1-based regimens and XELOX were For the possible differences in pharmacokinetics of S-1, and the differences regarding biology, epidemiology, stage, and prognosis of gastric cancer between Western countries and East Asians, when the S-1-based regimes are used as adjuvant chemotherapy for the whites, the dose should be carefully adjusted [8] . The previous study suggested that alternative 5-FU-containing regimens such as UFT or highdose 5-FU with or without cisplatin would be considered when financial constraints exist [37] ; however, our data suggested that 5-FU alone was not associated with a survival benefit for resected gastric cancer in term of OS.
For the DFS analysis, 5-FU/RT, S-1-based regimens, and XELOX showed a significant improvement in DFS as compared with surgery alone. There was no significant difference in DFS between 5-FU/RT, S-1-based regimens, and XELOX.
When we were focusing on the patients with D2 lymph node dissection, our study demonstrated that S-1-based regimens, UFT-based regimens, and XELOX improved both OS and DFS as compared with surgery alone. Adding radiation to 5-FU, however, provided little further survival benefit. The result that radiotherapy plus 5-FU was less effective in prolonging survival as compared with surgery alone might be due to the small sample sizes or random fluctuations in the subset analysis of INT 0116 trial [11] . For the subgroup analysis of stage III disease, there was no statistically significant difference between XELOX and S-1 in OS and DFS, suggesting the similar efficacy of the two treatments. How to select different adjuvant treatment for the stage III gastric cancer has been the focus of public attention in recent years and numerous trials have been conducted to explore the effectiveness of adjuvant chemotherapies such as S-1 plus oxaliplatin, S-1 plus docetaxel and S-1 plus cisplatin for stage III disease [16, [38] [39] [40] , reporting contrasting and sometimes equivocal results. The different trends in the adjuvant treatments for stage III gastric cancer warrant further evaluation in RCTs.
Nonetheless, some limitations in the present work merit further discussion. First, several RCTs were conducted over 2 decades and changes in the medical environment could particularly affect the control arms, which would influence the validity of the results. Second, our study was based on the meta-analysis of aggregate data from longitudinal clinical trials rather than individual patient data (IPD). Thus it was difficult for us to extract, calculate and compare survival data in the subgroups stratified by supposed predictors such as time span and stage classification. Staging modalities involved in the study varying across trials may potentially affect the results. However, only two trials reporting available data were included for subgroup analysis of stage III gastric cancer, the stage classification was according to the sixth edition of the AJCC cancer staging manual [23] , which resulted in slightly different population characteristics between this study and the current research [41] . Third, two trials [12, 42] investigating adjuvant platinum/docetaxel chemotherapy with or without radiation therapy and adjuvant capecitabine/cisplatin with or without radiation therapy were excluded for the shortage of trials which could connect the network nodes.
Despite these limitations, there are several strengths of our study. The absence of statistically significant inconsistency and publication bias in network meta-analysis confirmed the accuracy of our results and to the best of our knowledge, and this is the first attempt to systematically and quantitatively review the literature in this field. Moreover, inclusion criteria for enrolled trials were very similar, producing homogeneous populations and study characteristics for our study with the patients with resected gastric cancer. 
Conclusion
Our network meta-analysis provided the first comparisons between adjuvant treatments for patients with resected gastric cancer. S-1-based chemotherapy and XELOX are likely to be the most effective adjuvant treatments for patients with resected gastric cancer. 5-FU alone provided little survival benefits as compared with surgery alone. Further clinical trials may be required to investigate S-1-based and XELOXbased adjuvant treatment strategies.
